Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Galantamine Hydrobromide

FDA-approved product (tablet, oral), marketed as Galantamine Hydrobromide, Razadyne, Razadyne Er.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Galantamine Hydrobromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Dementia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anticholinesterases
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA35.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae89.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • K. pneumoniae: measured active in 1 of 1 lab record
Open Galantamine Hydrobromide in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Galantamine Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)

    NCT01039194 · start 2010-01

    Registered record
    Registry ID
    NCT01039194
    Conditions
    Alzheimer Disease
    Interventions
    galantamine; galantamine; BMS-708163
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-04
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Interventiongalantamine; galantamine; BMS-708163
    PhasePhase 1
    Registry statusCompleted

  • Galantamine Effects on Cognitive Function in Marijuana Users

    NCT00969696 · start 2009-08

    Registered record
    Registry ID
    NCT00969696
    Conditions
    Memory
    Interventions
    Placebo; Galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-08
    Completion
    2011-07
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMemory
    InterventionPlacebo; Galantamine
    PhasePhase 1
    Registry statusCompleted

  • The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia

    NCT02187276 · start 2009-06

    Registered record
    Registry ID
    NCT02187276
    Conditions
    Alzheimer Disease, Late Onset
    Interventions
    cholinesterase inhibitors
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-06
    Completion
    2013-03
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease, Late Onset
    Interventioncholinesterase inhibitors
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder

    NCT00741598 · start 2008-09

    Registered record
    Registry ID
    NCT00741598
    Conditions
    Bipolar Disorder
    Interventions
    Galantamine-ER; Galantamine placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2014-05
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionGalantamine-ER; Galantamine placebo
    PhasePhase 4
    Registry statusCompleted

  • Clinical Trial of Donepezil Between the Naive Group and the Switching Group

    NCT01023425 · start 2008-02

    Registered record
    Registry ID
    NCT01023425
    Conditions
    Alzheimer's Disease; Dementia
    Interventions
    donepezil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-02
    Completion
    2009-04
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease; Dementia
    Interventiondonepezil
    PhaseNot applicable
    Registry statusCompleted

  • Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

    NCT00606801 · start 2007-06

    Registered record
    Registry ID
    NCT00606801
    Conditions
    Cocaine Abuse
    Interventions
    Galantamine; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-06
    Completion
    2009-02
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Abuse
    InterventionGalantamine; placebo
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease

    NCT01734395 · start 2007-03

    Registered record
    Registry ID
    NCT01734395
    Conditions
    Alzheimer's Disease
    Interventions
    Galantamine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-01
    Enrolment
    1,882

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionGalantamine
    PhaseNot recorded
    Registry statusCompleted

  • The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease

    NCT01054976 · start 2006-10

    Registered record
    Registry ID
    NCT01054976
    Conditions
    Alzheimer's Disease
    Interventions
    Galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-10
    Completion
    2009-02
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionGalantamine
    PhasePhase 4
    Registry statusCompleted

  • Safety Study of Galantamine in Tic Disorders

    NCT00226824 · start 2005-09

    Registered record
    Registry ID
    NCT00226824
    Conditions
    Tourette's Syndrome; Motor Tic Disorder; Vocal Tic Disorder
    Interventions
    galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2005-09
    Completion
    2007-05
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourette's Syndrome; Motor Tic Disorder; Vocal Tic Disorder
    Interventiongalantamine
    PhasePhase 4
    Registry statusTerminated

  • Galantamine in the Treatment of Post-Traumatic Headache

    NCT00219869 · start 2005-07

    Registered record
    Registry ID
    NCT00219869
    Conditions
    Post-Traumatic Headache; Head Trauma,Closed; Retention Disorders,Cognitive
    Interventions
    Galantamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2005-07
    Completion
    2005-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Headache; Head Trauma,Closed; Retention Disorders,Cognitive
    InterventionGalantamine
    PhasePhase 4
    Registry statusUnknown

  • Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions

    NCT01190761 · start 2004-12

    Registered record
    Registry ID
    NCT01190761
    Conditions
    Healthy
    Interventions
    Galantamine 4 mg Tablet, single dose; Reminyl 4 mg Tablet, single dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-12
    Completion
    2004-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGalantamine 4 mg Tablet, single dose; Reminyl 4 mg Tablet, single dose
    PhasePhase 1
    Registry statusCompleted

  • The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease

    NCT01921972 · start 2004-11

    Registered record
    Registry ID
    NCT01921972
    Conditions
    Alzheimer's Disease
    Interventions
    Galantamine CR; Memantine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-11
    Completion
    2009-05
    Enrolment
    232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionGalantamine CR; Memantine; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Galantamine Executive Function in Parkinson's Disease

    NCT00211588 · start 2004-06

    Registered record
    Registry ID
    NCT00211588
    Conditions
    Parkinson's Disease
    Interventions
    galantamine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2004-06
    Completion
    2007-05
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    Interventiongalantamine
    PhaseNot applicable
    Registry statusUnknown

  • A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease

    NCT00297362 · start 2004-06

    Registered record
    Registry ID
    NCT00297362
    Conditions
    Alzheimer Disease
    Interventions
    Galantamine hydrobromide
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-10
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionGalantamine hydrobromide
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine

    NCT00297414 · start 2004-06

    Registered record
    Registry ID
    NCT00297414
    Conditions
    Mild Cognitive Impairment
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2004-06
    Completion
    2005-01
    Enrolment
    1,083

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment
    InterventionNo intervention
    PhaseNot recorded
    Registry statusCompleted